CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 105 enrolled
Drug / intervention
Insulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02988401
NCT02988401Phase 2Completed
CompareCT.gov

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Johns Hopkins University·interventional·Posted Dec 9, 2016·Updated Mar 10, 2023

In Brief

A Phase 2 clinical trial evaluating Insulin and Placebo (Sterile diluent) for Multiple Sclerosis, Relapsing-Remitting and 2 related conditions. Completed, enrolled 105 participants across 1 site.

Detailed Summary

This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS). It is also being done to evaluate if intranasal insulin improves cognitive function in people with MS and to evaluate how it might be working.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 9, 2016
Enrollment StartDec 1, 2017
Primary CompletionDec 17, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.6 years ago

Interventions

Insulindrug

All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.

Placebo (Sterile diluent)drug

All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.